Konsequenzen der Genauigkeit von Blutglucosemesssystemen

Hessel, Franz; Freckmann, Guido; Resch, Ansgar

doi:10.1007/s11428-013-1124-1

Cited by 4 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The population varied regarding age and treatment, one study only included employed patients (43). Five studies did not assess the actual costs but used models to estimate costs (35,41,(44)(45)(46). These studies often refer to previous studies for incidence rates and costs.…”

Section: Included Papersmentioning

confidence: 99%

“…Another study estimated direct speci c costs for two different types of insulin: €1671.11 (Exenatide BID twice daily) and €1887.27 (Liraglutide), respectively (55). The other studies report about prescription costs (54) and costs of treatment for hypoglycaemia (35,41). Average annual direct costs for severe hypoglycaemic events (inpatient and outpatient care) of patients with multiple daily insulin injections were €98.91 per patient with annually 0.1 hypoglycaemic events per patient (41).…”

Section: Diabetes Costs In Germanymentioning

confidence: 99%

“…The other studies report about prescription costs (54) and costs of treatment for hypoglycaemia (35,41). Average annual direct costs for severe hypoglycaemic events (inpatient and outpatient care) of patients with multiple daily insulin injections were €98.91 per patient with annually 0.1 hypoglycaemic events per patient (41). Average annual costs for hypoglycaemic episodes per patient are separated in inpatient €2434.74 and outpatient care €531.96, originating from annually 0,19 events per patient (35).…”

Section: Diabetes Costs In Germanymentioning

confidence: 99%

See 2 more Smart Citations

Costs and Its Drivers for Diabetes Mellitus Type 2 Patients in France and Germany: A Systematic Review of Economic Studies

Stegbauer¹,

Falivena

Moreno

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Type 2 diabetes represents an increasingly critical challenge for health policy worldwide. It absorbs massive resources for both patients and national economies to sustain direct and associated costs of treatment and indirect costs related to loss of work and wages. Last years are fuelling of innovations grounded on the remote control and personalised programs which are significantly improving the management of diabetes and the reduction of its related complications. In this view, this work attempts to update cost analysis reviews on type 2 diabetes, focusing on France and Germany, in order to explore most significant cost drivers and rooms for cost savings by technology advancement. Although characterized by different approaches in delivering care, France and Germany represent the primary European markets for diabetes technologies. Methods A systematic review of the literature was carried out in MEDLINE, Embase and EconLit for interventional, observational, and modelling studies on expenditures for type 2 diabetes management in France or Germany published since 2012. Included articles were analysed for annual direct, associated, and indirect costs of type 2 diabetes patients. An appraisal of study quality was performed. Results are summarised narratively. Results From 1.260 records, the final sample was composed of 24 papers selected according to predefined inclusion/exclusion criteria. Both France and Germany revealed a predominant focus on direct cost. Comparability was limited due to different study populations and cost categories used. Nevertheless, France seems to reimburse higher direct costs than Germany. Indirect costs were only available for Germany. According to prior literature, reported cost drivers are hospitalisation and prescriptions as well as higher HbA1c and BMI, treatment with insulin and complications all indicating the severity of the disease. Diversity in available data and in included costs limit the results and may explain differences found. Conclusions Preventing complications and glycaemic control are widely recognized as the most effective ways to govern the expenditure for the treatment of diabetes. The implementation of self-based supports, such as hybrid closed-loop metabolic, already implemented for type 1 diabetes management, are the key pillars for further debates and policymaking, involving the perspectives of both caregivers and patients.

show abstract

Section: Included Papersmentioning

confidence: 99%

Section: Diabetes Costs In Germanymentioning

confidence: 99%

Section: Diabetes Costs In Germanymentioning

confidence: 99%

See 1 more Smart Citation

Costs and Its Drivers for Diabetes Mellitus Type 2 Patients in France and Germany: A Systematic Review of Economic Studies

Stegbauer¹,

Falivena

Moreno

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Of these papers, nine papers report 165 cost items on diabetes costs in France (51-59) (all direct costs) and 16 papers report 135 cost items on diabetes costs in Germany of which 131 describe direct costs (36,(59)(60)(61)(62)(63)(64)(65)(66)(67)(68)(69)(70)(71)(72)(73). Cost assessment was based on different numbers of patients ranging from 32 patients in a study performing a survey (72) up to 2.7 million patients in a study analysing health insurance claims data (62).…”

Section: Included Papersmentioning

confidence: 99%

Costs and its Drivers for Diabetes Mellitus Type 2 Patients in France and Germany: A Systematic Review of economic studies

Stegbauer¹,

Falivena

Moreno

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Type 2 diabetes represents an increasingly critical challenge for health policy worldwide. It absorbs massive resources from both patients and national economies to sustain direct costs of the treatment of type 2 diabetes and its complications and indirect costs related to work loss and wages. More recently, there are innovations based on remote control and personalised programs that promise a more cost-effective diabetes management while reducing diabetes-related complications. In this context, this work attempts to update cost analysis reviews on type 2 diabetes, focusing on France and Germany, in order to explore most significant cost drivers and cost-saving opportunities through innovations in diabetes care. Although both countries approach care delivery differently, France and Germany represent the primary European markets for diabetes technologies.Methods: A systematic review of the literature listed in MEDLINE, Embase and EconLit has been carried out. It covered interventional, observational and modelling studies on expenditures for type 2 diabetes management in France or Germany published since 2012. Included articles were analysed for annual direct, associated and indirect costs of type 2 diabetes patients. An appraisal of study quality was performed. Results: were summarised narratively. Results From 1.260 records, the final sample was composed of 24 papers selected according to predefined inclusion/exclusion criteria. Both France and Germany revealed a predominant focus on direct costs. Comparability was limited due to different study populations and cost categories used. Indirect costs were only available in Germany. According to prior literature, reported cost drivers are hospitalisation, prescriptions, higher HbA1c and BMI, treatment with insulin and complications, all indicators of disease severity. The diversity of available data and included costs limits the results and may explain the differences found. Conclusions: Complication prevention and glycaemic control are widely recognized as the most effective ways to control diabetes treatment costs. The value propositions of self-based supports, such as hybrid closed-loop metabolic systems, already implemented in type 1 diabetes management, are the key points for further debates and policymaking, which should involve the perspectives of caregivers, patients and payers.

show abstract

“…Hierfür können systematische Unterschiede durch unterschiedliche Kalibration verantwortlich sein, aber auch Anwendungsfehler durch den Benutzer. Präanalytisch haben der Hämatokrit, die Umgebungstemperatur und die Teststreifen-Charge einen Ein uss auf die Messgenauigkeit[1,2].…”

unclassified

Was können Sensor, Pumpe, Bolusrechner?

Schlüter¹

2015

Info Diabetol

View full text Add to dashboard Cite

Am Einsatz von Technik kommt inzwischen kaum ein Diabetespatient bei seiner Therapiesteuerung mehr vorbei. Die Blutzuckerselbstmessung war nur der Anfang einer Kette von Geräten, Software und weiterem Zubehör. Dabei ist neben der Kosten-Nutzen-Frage noch mehr zu bedenken: Denn der richtige Umgang mit Sensor, Rechner und Co. will geschult und gelernt sein. Technologie bekommt einen immer größeren Stellenwert in der Diabeteswelt. War es vor 30 Jahren revolutionär Blutzucker-Selbstmessung durchzuführen, ist heute eine Diabetestherapie ohne Diabetestechnologie nicht mehr vorstellbar. Viele technische Hilfsmittel sind bereits als Standard im Alltag der Patienten etabliert. Und da sprechen wir nicht von einem neuen Schli der Insulinpennadel oder wie viele Einheiten ein Insulinpen in der Lage ist, maximal zu injizieren. Es geht um Technologien, die erapieentscheidungen erleichtern, etwa Insulindosisrechner, oder die Ereignisse in der nahen Zukun berechnen und selbstständig eine erapieentscheidung fällen wie die prädiktive Hypoglykämieabschaltung in Insulinpumpensystemen. Durch diese neue Technologie verändert sich die Wahrnehmung des Diabetes für die Patienten, aber auch für die Behandler. Dabei ist zu beachten, dass die erapie nicht zwangsläu g einfacher wird durch die Nutzung unterschiedlicher Technik. Die Technologie muss durch den Anwender gesteuert werden. Er muss wissen, wann ist die Technik einzusetzen, wie ist auf die erhaltene Information zu reagieren. Dieses Wissen muss erlernt werden. Daher sind Fortbildungen und Schulungsprogramme für Anwender und medizinisches Fachpersonal zwin-gend erforderlich. Erst die Kombination aus Wissen und Technologie ist eine sichere Hilfe im Alltag. Die aktuell verfügbare Diabetestechnologie kann die erapie nicht autonom führen. © Kerstin Waurick / iStock.com Moderne Diabetes-Technologie erleichtert Vieles. Die Denkarbeit nimmt zum Teil aber sogar zu. fortbildung 45 IN | Fo | DIABETOLOGIE  2015; 9 (3) fortbildung

show abstract

Konsequenzen der Genauigkeit von Blutglucosemesssystemen

Cited by 4 publications

References 21 publications

Costs and Its Drivers for Diabetes Mellitus Type 2 Patients in France and Germany: A Systematic Review of Economic Studies

Costs and Its Drivers for Diabetes Mellitus Type 2 Patients in France and Germany: A Systematic Review of Economic Studies

Costs and its Drivers for Diabetes Mellitus Type 2 Patients in France and Germany: A Systematic Review of economic studies

Was können Sensor, Pumpe, Bolusrechner?

Contact Info

Product

Resources

About